Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes-Reference-Cited by-同舟云学术

Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes

Published:2022-06 Issue:6 Volume:12 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Wang Qianqian¹,Li Jun¹,Zhu Jing²,Mao Jiaqi³,Duan Chao³,Liang Xiao¹,Zhu Lingyun³,Zhu Mengyan⁴,Zhang Zhihong⁵,Lin Fan³,Guo Renhua¹^ORCID

Affiliation:

1. Department of Oncology the First Affiliated Hospital of Nanjing Medical University Nanjing China

2. Department of Oncology the Affiliated Jiangning Hospital of Nanjing Medical University Nanjing China

3. Department of Cell Biology School of Basic Medical Sciences Institute for Brain Tumors & Key Laboratory of Rare Metabolic Diseases Nanjing Medical University Nanjing China

4. Department of Bioinformatics Nanjing Medical University Nanjing China

5. Department of Pathology the First Affiliated Hospital of Nanjing Medical University Nanjing China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.882

Reference38 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. The biology and management of non-small cell lung cancer

3. Scientific Advances in Lung Cancer 2015

4. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

5. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer;Molecular Carcinogenesis;2024-06-11

2. Genome‐scale CRISPR–Cas9 screen identifies PAICS as a therapeutic target for EGFR wild‐type non‐small cell lung cancer;MedComm;2024-03

3. Applications of CRISPR screening to lung cancer treatment;Frontiers in Cell and Developmental Biology;2023-12-15

4. CRISPR/Cas9 screening reveals that ASB2 inhibits p53-dependent ferroptosis to mediates Lenvatinib resistance in hepatocellular carcinoma;2023-01-09

5. Ten Years of CRISPRing Cancers In Vitro;Cancers;2022-11-23